title: N-acetylcysteine fails to prevent renal dysfunction and oxidative stress after noniodine contrast media administration during percutaneous coronary interventions.
abstract: BACKGROUND
  Oxidative stress is believed to have a role in contrast-induced nephropathy. Based on this assumption, several known antioxidants have been studied to assess their effect on nephropathy, especially N-acetylcysteine (NAC). However, its usefulness has yet to be confirmed.
  
  
  OBJECTIVE
  We aimed to assess whether NAC has any protective effect on contrast-induced renal dysfunction, and whether NAC affects the parameters of oxidative stress in serum and urine.
  
  
  METHODS
  Sixty patients with coronary artery disease, who presented for an elective percutaneous coronary intervention (PCI), were randomized into 2 groups in an age- and gender-matched fashion: one group received 600 mg intravenous NAC and the other did not. Before and 24 hours after the procedure, blood and urine samples were obtained to assess total oxidant capacity (TOC), total antioxidant capacity (TAC), oxidative stress index (OSI), and renal function.
  
  
  RESULTS
  Twenty-four hours after PCI, TOC and OSI levels were significantly increased and TAC levels significantly decreased, both in serum and urine. However, we did not observe any differences in oxidative parameters between patients who received NAC and those who did not. Multivariate analyses identified no protective effect of NAC on renal function, and no effect on oxidative parameters in either serum or urine.
  
  
  CONCLUSIONS
  In this first clinical study that determined TOC and TAC levels in both serum and urine after exposure to contrast media, NAC was not found to affect oxidant parameters or protect against contrast nephropathy, at least in patients without the risk factors for nephropathy, such as diabetes mellitus or baseline renal or cardiac dysfunction.
authors.affiliation: Harran University School of Medicine, Department of Internal Medicine, Sanliurfa, Turkey. buyukhatipoglu@gmail.com
authors.forename: Hakan
authors.initials: H
authors.lastname: Buyukhatipoglu
authors.forename: Yusuf
authors.initials: Y
authors.lastname: Sezen
authors.forename: Ali
authors.initials: A
authors.lastname: Yildiz
authors.forename: Memduh
authors.initials: M
authors.lastname: Bas
authors.forename: Idris
authors.initials: I
authors.lastname: Kirhan
authors.forename: Turgay
authors.initials: T
authors.lastname: Ulas
authors.forename: Mehmet Nuri
authors.initials: MN
authors.lastname: Turan
authors.forename: Abdullah
authors.initials: A
authors.lastname: Taskin
authors.forename: Nurten
authors.initials: N
authors.lastname: Aksoy
mesh_terms: D000111:Acetylcysteine / Q000008:administration & dosage* / Q000627:therapeutic use; D058186:Acute Kidney Injury / Q000139:chemically induced* / Q000517:prevention & control*; D000368:Aged; D015906:Angioplasty, Balloon, Coronary / Q000009:adverse effects; D003287:Contrast Media / Q000009:adverse effects*; D017023:Coronary Angiography / Q000009:adverse effects; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D018384:Oxidative Stress / Q000187:drug effects; D016896:Treatment Outcome
chemical_list: D003287:Contrast Media; D000111:Acetylcysteine